R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconjunctivitis Sicca
Conditions
Keratoconjunctivitis Sicca
Trial Timeline
Nov 1, 2012 → Feb 1, 2013
NCT ID
NCT01733992About R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo is a phase 1 stage product being developed by Rigel Pharmaceuticals for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT01733992. Target conditions include Keratoconjunctivitis Sicca.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01733992 | Phase 1 | Completed |
Competing Products
15 competing products in Keratoconjunctivitis Sicca
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK506 | Astellas Pharma | Phase 3 | 77 |
| FK506 + placebo | Astellas Pharma | Phase 3 | 77 |
| OTX-101 0.09% | Sun Pharmaceutical | Phase 3 | 77 |
| OTX-101 0.05% + OTX-101 0.09% + Vehicle | Sun Pharmaceutical | Phase 2/3 | 65 |
| cyclosporine + vehicle of OTX-101 | Sun Pharmaceutical | Phase 3 | 77 |
| INS365 Ophthalmic Solution | Merck | Phase 3 | 77 |
| Pimecrolimus + Vehicle | Novartis | Phase 2 | 52 |
| Cyclosporine A + Dexamethasone | Novartis | Approved | 85 |
| Rebamipide | Novartis | Phase 3 | 77 |
| Rebamipide | Novartis | Phase 3 | 77 |
| Tasocitinib + Tasocitinib + vehicle for Tasocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo | Rigel Pharmaceuticals | Phase 2 | 44 |
| CF101 | Can Fite Biopharma | Phase 3 | 69 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 44 |